

Date : March, 2016

Dear Customers,

**Re: TRANSFER OF BUSINESS FROM SUMMIT PHARMACEUTICALS
INTERNATIONAL TO SUMITOMO CORPORATION**

We, Summit Pharmaceuticals International Corporation (“SPI”), take great pleasure in announcing, that all the trading business of veterinary drug handled by our Pharmaceuticals & Fine Chemicals Dept. No.1 will be transferred to PetCare Science Dept. of Sumitomo Corporation (“SC”, our parent company) as of April 1st, 2016.

In 2004 SC ventured into the pet care business in the US, the world’s largest pet market, by acquiring the pet care products manufacturer The Hartz Mountain Corporation. SC recently entered the veterinary drug business in China by acquiring the shares of Chinese veterinary vaccine manufacturer.

By integrating the veterinary drug business in SC, we assure that SC can provide you and your clients with more comprehensive service through the international network of SC group.

For more details on this business transfer, please contact following attention.

Summit Pharmaceuticals International Corp. Pharmaceuticals & Fine Chemicals Dept. No.1

TEL: +81-3-3536-8935 (Contact Person : Shingo Hamao)

E-Mail : info@summitpharma.co.jp

Your kind understanding on this business transfer would be highly appreciated.

Sincerely yours,

Yoshiki Terawaki

President

Summit Pharmaceuticals International Corporation

**Summit Pharmaceuticals International Corporation
(a SUMITOMO CORPORATION GROUP company)
Harumi Island Triton Square Office Tower Z, 1-8-12 Harumi, Chuo-ku, Tokyo
104-6223 Japan**

<http://www.summitpharma.co.jp/>